Merck KGaA to Acquire Bio-Techne for $11.3 Billion
German pharmaceutical and life sciences firm Merck KGaA has agreed to acquire US-based Bio-Techne Corporation in a $11.3 billion deal, marking its largest acquisition since the Sigma-Aldrich purchase in 2015. The transaction is expected to strengthen Merck's presence in the life sciences sector by adding key products such as cytokines and immunoassay kits.
Tickers: $TECH